Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
GENR received an SPA from FDA for two identical international Phase III trials of Evizon squalamine lactate to treat choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). G...
